AVADEL PHARMACEUTICALS Aktie

Asset manager Janus Henderson Group plc disclosed a 1.87% stake in Avadel Pharmaceuticals, holding 1,821,975 common shares, of which voting rights cannot be exercised for 63,215 shares. The position was reported as of January 6; Janus Henderson also sold 490 Avadel shares at $21.4750 per share. The disclosure was made as a Form 8.3 under Irish takeover rules and is not in connection with any other party in a possible offer situation; Avadel has not publicly commented. » More on de.investing.com

Morgan Stanley & Co. LLC disclosed that on December 23, 2025 it purchased 186,810 common shares of Avadel Pharmaceuticals at prices between $21.46 and $21.63 and sold 179,270 shares at prices between $21.45 and $21.63. The bank is named as an affiliated party in connection with an unspecified offer or potential transaction. No cash-settled or delivery-obligated derivatives were reported; the disclosure was made in accordance with Irish takeover rules. » More on de.investing.com

The investment firm Citadel has, by mandatory notification, disclosed a 1.09% stake in Avadel Pharmaceuticals (1,070,764 shares). At the same time Citadel holds short positions totaling 0.97% of the shares, partly via equity-based derivatives. The filing lists transactions from December 22 at prices between $21.43 and $21.60 and was made as Form 8.3 under the rules of the Irish Takeover Panel; no takeover offer is reported. » More on de.investing.com